hnRNP A1 KNOCKOUT ANIMAL MODEL AND USE THEREOF
A nucleic acid construct comprising a genetic engineered heterogeneous nuclear ribonucleoprotein (hnRNP) A1 gene is provided. A transgenic mouse in which the expression of hnRNP A1 gene has been disrupted is also provided. The mouse is useful for studying the role of hnRNP A1 gene in normal and disease states of a neurodegenerative disease or a cancer for developing therapies to treat any of these diseases. Therefore, a method of screening a compound for potential use in prevention and/or treatment of neurodegenerative disease or cancer is further provided.
Latest KAOHSIUNG MEDICAL UNIVERSITY Patents:
1. Technical Field
The present disclosure relates to vectors comprising Heterogeneous nuclear ribonucleoprotein (hnRNP) A1 gene and non-human animals in which the expression of hnRNP A1 gene has been disrupted.
2. Description of Related Art
Heterogeneous nuclear ribonucleoprotein (hnRNP) A1 is a protein that has been reported to play a significant part in regulating the process of gene splicing (Del Gatto-Konczak et al., 1999 MOI Cell Biol 19, 251-260), telomere extension (LaBranche et al., 1998 Nat Genet 19, 199-202), and viral replication (Lin et al., 2009 J Virol 83, 6106-6114; Monette et al., 2009, J Biol Chem 284, 31350-31362), and any of the identified cellular events has been implicated with diseases including cancerous progression carcinogenesis, and neurodegenerative disease.
Recently, hnRNP A1 is identified to be involved in alternative splicing of many disease-related proteins, such as GTPase Rac1 and carcinoembryonic antigen-related cell adhesion molecule-1 (CEACAM1). Rac1b, an alternatively spliced isoform of Rac1, was originally identified as an over-expressed protein in breast and colorectal cancer cells, and has subsequently been suggested an important role in many oncogenic signaling pathways. CEACAM1 is expressed in a variety of cell types, including breast cancer cells, and is also implicated in carcinogenesis. Alternative splicing of Exon 11 of the insulin receptor gene (INSR), which is developmental stage-dependent and tissue-specific, is also regulated by hnRNP A1. hnRNP A1 inhibites exon 11 inclusion and results in insulin receptor-B (IR-B) expression, which predominantly express in insulin-sensitive tissue, suggesting a metabolic role (Talukdar et al., PLoS One (2011), 6: e27869). It is demonstrated that hnRNP A1 is a negative factor to splicing selection of Ataxia Teleangectasia Mutated gene (ATM), the gene mutated in an autosomal recessive disorder characterized by cerebellar ataxia and oculocutaneous telangiectasias (Pastor et al., PLoS One (2011), 6: e23349).
In view of the role of hnRNP A1 associated with various diseases, it is useful to provide an animal model, particularly, a hnRNP A1 knockout model, in which the expression level of hnRNP A1 protein is not expressed in null mice and the expression level of hnRNP A1 in the heterozygous in the knockout model is relatively low, as compared to a normal animal, for further studies on the function of hnRNP A1 gene in any of the identified diseases and its use in developing therapies to treat any of these diseases.
SUMMARYAs embodied and broadly described herein, disclosure herein features vectors comprising hnRNP A1 gene and non-human animals and cell lines in which the expression of hnRNP A1 gene has been disrupted.
Accordingly, in one aspect, the present disclosure is directed to a targeting vector or a nucleic acid construct, which includes a nucleic acid sequence, in which a first locus of recombination sequence 1 is inserted before the exon 2 of the endogeneous hnRNP A1 gene, and second recombination sequences 2 flanking a marker gene followed by a second locus of recombination sequence 1 is inserted behind the exon 8 of the endogenous hnRNP A1 gene.
In another aspect, the present disclosure is directed to a cell containing the nucleic acid construct of the present invention or a disrupted hnRNP A1 gene. Preferably, the cell is a stem cell, and more preferably, an embryonic stem (ES) cell, and most preferably, a murine ES cell. According to one embodiment, the cell is produced by introducing the nucleic acid construct of the present invention into a stem cell to produce a homologous recombinant, resulting in a disruption in the hnRNP A1 gene, in which the neomycin resistant gene and the exons 2 to 8 of the hnRNP A1 gene are respectively deleted by the introduction of FLP recombinase and Cre recombinase.
In still another aspect, the present disclosure provides a non-human animal and its progeny having a disruption in hnRNP A1 gene. In one embodiment, the non-human animal and its progeny are heterozygous or homozygous for a null mutation in the hnRNP A1 gene. In another embodiment, the non-human animal and its progeny having a disruption in hnRNP A1 gene exhibit decreased expressed levels of the hnRNP A1 gene, relative to the wild-type non-human animals. Preferably, the non-human animal and its progeny are rodents and, most preferably, are mice.
In a further aspect, the present disclosure provides a method of obtaining a non-human animal deficient in hnRNP A1 gene, or with decreased or null expressed level of hnRNP A1 gene. The method includes steps of inserting into the genome of the embryonic stem cell derived from the non-human animal the nucleic acid construct of the present invention, injecting the embryonic stem cell into a blastocyst of the non-human animal after introduction of appropriate recombinase, and implanting the blastocyst into the uterus of a foster mother. Preferably, the non-human animal is rodent and, most preferably, is mouse.
The non-human animals of the present disclosure are useful for studying hnRNP A1 gene and diseases wherein hnRNP A1 gene is implicated, including neurodegenerative disease and cancer. The non-human animals of the present disclosure are useful for identifying therapeutic compounds that may be useful in preventing and/or treating any of these diseases.
Accordingly, in still a further aspect, the present disclosure provides a method of screening a compound for potential use in modulating the function of the hnRNP A1 gene that linked to the prevention and/or treatment of neurodegenerative disease or cancer. The method includes steps of respectively administering a test compound to the non-human animal deficient in hnRNP A1 gene and a wild-type non-human animal or cells or tissues derived therefrom; and assessing the function of exonic RNA splicing in each of the non-human animal, cells, or tissues defined above, prior to and after a given time period of the administration; and comparing the non-human animal deficient in hnRNP A1 gene with the wild-type non-human animal in terms of the test results to determine effectiveness of the test compound. Preferably, the non-human animal is rodent and, most preferably, is mouse.
The details of one or more embodiments of the invention are set forth in the description below. Other features, objects, and advantages of the present invention will be apparent from the description, and from the claims.
The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
The present description will be better understood from the following detailed description read in light of the accompanying drawings.
The detailed description provided below in connection with the appended drawings is intended as a description of the present examples and is not intended to represent the only forms in which the present example is constructed or utilized. The description sets forth the functions of the examples and the sequence of steps for constructing and operating the examples. However, the same or equivalent functions and sequences may be accomplished by different examples.
1. Definitions
The terms “a”, “an”, and “the” as used herein are defined to mean “one or more” and include plural referents unless the context clearly dictates otherwise.
The term “gene” refers to a gene containing at least one of the DNA sequence disclosed herein, or any DNA sequence encodes the amino acid sequence encoded by the DNA sequence disclosed herein, or any DNA sequence that hybridizes to the complement of the coding sequence disclosed herein. Preferably, the term includes coding and non-coding regions, and preferably all sequences necessary for normal gene expression including promoters, enhancers, and other regulatory sequences.
The term “nucleic acid” refers to polymeric forms of nucleotides of any length. The nucleic acid may contain deoxyribonucleotides, ribonucleotides, and/or their analogs. Nucleotides may have any three-dimension structure, and may perform any function, known or unknown. The term “nucleic acid” includes single-, double-stranded and triple helical molecules. Non-limited examples of nucleic acids include, but are not limited to, a gene or its fragment, exons, introns, mRNA, tRNA, rRNA, ribozymes, cDNA, recombinant nucleic acid, plasmids, vectors, isolated DNA or RNA of any sequence, nucleic acid probes and primers. A nucleic acid may also comprise modified nucleic acid molecules, such as methylated nucleic acid molecules and nucleic acid analogs.
The term “homologous recombination” refers to exchange DNA fragments between two DNA molecules at the site of homologous nucleotide sequence.
The term “homologous” are used herein to denote a characteristic of a DNA sequence having at least 70% sequence identity as compared to a reference sequence, typically at least about 85% sequence identity, preferably at least about 95% sequence identity, and more preferably about 98% sequence identity, and most preferably about 100% sequence identity as compared to a reference sequence. Homology can be determined using, for example, a “BLASTN” algorithm. It is understood that homologous sequence may accommodate insertions, deletions, and substitutions in the nucleotide sequence. Thus, linear sequence of nucleotides can be essentially identical even if some of the nucleotides residues do not precisely correspond or align. The reference sequence may be a subset of a large sequence, such as a portion of a gene or flanking sequence.
“Disruption” of an hnRNP A1 gene occurs when a fragment of genomic DNA locates and recombines with an endogenous homologous sequence. These sequence disruptions or modifications may include insertions, missense, framshift, deletion, substitutions, or replacement of DNA sequence, or any combinations thereof. Insertions include the insertion of the entire genes, which may be of any origin. Disruption, for example, can alter or replace a promoter, an enhancer or splice site of the hnRNP A1 gene, and can alter the normal gene product by inhibiting its production partially, or completely. In a preferred embodiment, the disruption is a null disruption, wherein there is no significant expression of the hnRNP A1 gene.
The practices of this invention are hereinafter described in detail with respect to targeting vectors or nucleic acid constructs comprising a nucleic acid sequence comprising hnRNP A1 gene; and non-human animals in which the expression of hnRNP A1 gene has been disrupted. Among other uses and applications, the animal model developed in this invention are useful in various screening assays for the identification of therapeutically useful compounds for the treatment of diseases and/or conditions involving the expression of hnRNP A1 gene.
2. Generation of the Targeting Vector or Nucleic Acid Construct
In order to prepare a knockout animal, a targeting vector or nucleic acid construct containing hnRNP A1 gene is constructed. The nucleic acid construct is designed to disrupt the expression of hnRNP A1 gene in a cell. The general features of the nucleic acid construct are that it contains a nucleic acid sequence from one or more regions of the hnRNP A1 gene.
Accordingly, in one aspect, the present disclosure provides a vector or a nucleic acid construct, which includes a genetic engineer heterogeneous nuclear ribonucleoprotein (hnRNP) A1 gene, wherein a first locus of recombination sequence 1 is inserted before exon 2 of the hnRNP A1 gene, and recombination sequences 2 (i.e. a first locus and a second locus of the recombination sequences 2) flanking a marker gene followed by a second locus of recombination sequence 1 are inserted behind exon 8 of the hnRNP A1 gene. The recombination sequence 1 at the first locus undergoes recombination with the recombination sequence 1 at the other locus in the presence of its corresponding recombinase. Similarly, the recombination sequence 2 at the first locus undergoes recombination with the recombination sequence 2 at the other locus in the presence of its corresponding recombinase. Of note is that, the recombination sequence 1 and the recombination sequence 2 belong to different recombination sequence/recombinase system. In one embodiment, the recombination sequence 1 and its corresponding recombinase belong to Cre/loxP system, and the recombination sequence 2 and its corresponding recombinase belong to FLP/frt (FLP recombination target) system. More specifically, the hnRNP A1 gene is disrupted by introduction of Cre recombinase and FLP recombinase.
The Cre/loxP system is a well known system for artificially control gene expression (Kuhn and Torres, 2002 Methods Mol Biol 180: 175-204). The system begins with the cre gene, which encodes a site-specific DNA recombinase named Cre or cyclic recombinase. A site-specific DNA recombinase means that the Cre protein recombines DNA when it locates specific sites in a DNA molecule. These sites are known as loxP or locus of crossover (x) in P1 sequences (SEQ ID NO: 1). When cells that have loxP sites in their genome also express Cre, the protein may catalyze a reciprocal recombination event between the loxP sites, which means the double stranded DNA is cut at both loxP sites by the Cre protein and then ligated back together. As a result, the DNA between the loxP sites is excised as a circular DNA and subsequently degraded. In order to prepare the nucleic acid construct, the genomic DNA sequence of hnRNP A1 gene (SEQ ID NO: 2) is digested with restriction enzymes and the loxP sites are ligated into the genomic DNA sequence at desired locations using methods known to those skill artisans or as described in Examples of this application. The FLP/frt system is functionally analogous to the Cre/loxP system. Further examples of recombinases include, but are not limited to, lambda Int protein, IHF, Xis, Hin, Gin, Cin, Th3 resolvase, TndX and XerD. As to recombination sequences (sites), examples include, but are not limited to, loxP site, frt site (SEQ ID NO: 3), att site, six sites, res sites, rox sites, psi sites and cer site (see WO2001/1042590).
A marker gene used for selection may be included in the nucleic acid construct, so as to identify cells that have been successfully transfected with the nucleic acid construct of the present invention. The marker gene can be any marker that can be used to detect the presence of the nucleic acid in a cell. Preferred marker genes are antibiotic resistance genes such as neomycin-resistant gene (Neo, SEQ ID NO:
4), the reporter lacZ gene and the herpes simplex virus thymidine kinase gene (HSV-tk). In one embodiment, the marker sequence is a neomycin-resistant gene. The marker gene may be inserted with recombination sequences flanking each end of it.
In a preferred embodiment of the present invention, the nucleic acid construct is generated by first amplifying sequence homologous to the target sequence (such as the hnRNP A1 gene) and then inserting the loxP sequences, and a neomycin resistant gene in combination with frt sequences at each end into the amplified product so that it is flanked by the homologous sequence. Specifically, a loxP sequence is inserted before the exon 2 of the endogeneous hnRNP A1 gene, and FLP recombinase target (frt) sequences flanking a neomycin-resistant gene followed by another loxP sequence is inserted behind the exon 8 of the endogenous hnRNP A1 gene. More specifically, the first locus of loxP sequence is inserted between the exon 1 and exon 2 of the endogeneous hnRNP A1 gene, and the neomycin-resistant gene flanked by frt sequences and the second locus of loxP sequence are inserted between exon 8 and exon 9. Preferably, the nucleic acid construct is as depicted in
The nucleic acid construct containing the hnRNP A1 gene, the Cre/lox system and the marker gene can be inserted directly into appropriate host cells such as embryonic stem cells as will be described below or it may be placed in suitable vectors for amplification prior to insertion.
3. Generation of the Transfected Embryonic Stem Cells
The above nucleic acid constructs or vectors may be transfected into an appropriate host cell using any method known in the art. Various techniques may be employed for such purpose, which include and are not limited to, microinjection of DNA into the nucleus, retrovirus mediated gene transfer into germ lines, electroporation of embryos, sperm-mediated gene transfer, and calcium phosphate/DNA co-precipitates, transfection or the like.
In a preferred embodiment, the nucleic acid construct is transfected into host cells by electroporation. In this process, electrical impulses of high field strength reversibly permeabilize biomembranes allowing the transfection of the nucleic acid construct. The pores created during electroporation permit the uptake of macromolecules such as DNA into the host cells.
Any cell type capable of homologous recombination may be used to practice this invention. Preferred cell types include embryonic stem (ES) cells, which are typically obtained from pre-implantation embryos cultured in vitro. The ES cells are cultured and prepared for transfection of the nucleic acid construct using methods known in the related art. The ES cells that will be transfected with the targeting vector or nucleic acid construce are derived from embryo or blastocyst of the same species as the developing embryo or blastocyst into which they are to be introduced. ES cells are typically selected for their ability to integrate into the inner cell mass and contribute to the germ line of an individual when introduced into the animal in an embryo at the blastocyst stage of development. In one embodiment, the ES cells are isolated from the mouse blastocysts, in another embodiment, from the 129/SvJ strain.
After transfection into the ES cells, the nucleic acid construct integrates with the genomic DNA of the cell in order to delet the transcription of the native hnRNP A1 gene. Preferably, the insertion occurs by homologous recombination wherein regions of the hnRNP A1 gene in the nucleic acid construct hybridize to the homologous hnRNP A1 sequence in the ES cell and recombine to incorporate the construct into the endogenous hnRNP A1 gene.
After transfection, the ES cells are cultured under suitable condition to detect transfected cells. For example, when the marker gene comprises an antibiotic resistant marker, the cells are cultured in that antibiotic. In one embodiment, the neomycin resistant gene is present, and the ES cells are exposed to neomycin analog, G418. ES cells that express the introduced neomycin (Neo) resistant gene are resistant to the compound G418, whereas ES cells that do not carry the Neo gene marker cannot survive. The DNA and/or protein expression of the surviving ES cells may be analyzed using Southern Blot technology and/or Western Blot technology as described in the Examples of this application, in order to identify the ES cells with the proper integration of the construct. The neomycin resistant gene is then removed by the introduction of FLP recombinase; and the hnRNP A1 gene segment flanked by the two loxP sequencess, or more specifically the exons 2 to 8 of hnRNP A1 gene, of the survived ES cells may then be removed by the introduction of Cre recombinase.
4. Generation of the Knockout Animals
The selected ES cells are then injected into a blastocyst of a non-human animal to form chimeras. The non-human animal may be a mouse, a hamster, a rat or a rabbit. Preferably, the non-human animal is a mouse. In particular, the ES cells are inserted into an early embryo using microinjection. For microinjection, 10 to 20 ES cells are collected into a micropipette and injected into 3 to 5 day old bastocysts recovered from female mice. The injected blasocysts are re-implanted into a foster mother. When the pups are born, typically 18 to 20 days later, they are screened for the presence of nucleic acid construct of this invention. In one embodiment, DNA collected from the tail tissues of the pups may be screened using Southern Blot and/or PCR technique as described in Examples of this disclosure. The heterozygotes are identified and are then crossed with each other to generate homologous knockout animals.
Accordingly, the present invention provides a transgenic non-human animal and its progeny, whose genome comprising a disruption in hnRNP A1 gene, wherein the animal has a decreased (i.e., heterozygous disruption) or null (i.e., homozygous disruption) expression level of the hnRNP A1 gene as compared to that of a wild-type animal. The present invention also provides cells or tissues, including immortalized cell lines and primary cells or tissues, derived from the transgenic non-human animal and its progeny. The expression of the hnRNP A1 gene may be partially or completely disrupted. In the case when a complete disruption occurs, the level of hnRNP A1 gene is not detectable by Southern blotting. In one embodiment, the disruption affects at least two exons within the hnRNP A1 gene. In another embodiment, the exons are exons 2 to 8.
In one embodiment, the transgenic non-human animal and its progeny are mice, hamsters, rats or rabbits. In another embodiment, the transgenic non-human animal and its progeny are mice. The homozygous disruption in the hnRNP A1 gene of the transgenic mouse results in damaged function of exonic RNA splicing, a reduced weight relative to a wild-type control mouse at embryonic stage, and/or perinatal mortality. Furthermore, the transgenic mouse with heterozygous disruption in the hnRNP A1 gene is predisposed to premature aging diseases and/or virus infective diseases.
The present invention further provides a method of preparing transgenic non-human animal with decreased or null expression level of hnRNP A1 gene comprising steps of inserting into the genome of the embryonic stem cell derived from the non-human animal the nucleic acid construct of the present invention, injecting the embryonic stem cell into a blastocyst of the non-human animal after introduction of appropriate recombinases, and implanting the blastocyst into the uterus of a foster mother of the non-human animal. In one embodiment, the non-human animal is a mouse, a hamster, a rat or a rabbit. In another embodiment, the non-human animal is a mouse.
In a preferred embodiment, the method includes steps of: (1) obtaining a nucleic acid sequence containing a hnRNP A1 gene or a portion thereof; (2) preparing a nucleic acid construct of the present invention; (3) transfecting the nucleic acid construct into an ES cell; (4) selecting an ES cells that has integrated the nucleic acid construct into its genome; (5) introducing FLP and Cre recombinases to the selected ES cells in step (4) to remove the marker gene and exons 2 to 8 of the hnRNP A1 gene and generate a deleted hnRNP A1 gene; (6) introducing the selected ES cell in step (5) into a blastocyst to form a chimera blastocyst; (7) implanting the chimeric blastocyst into a pseudopregnant mother, wherein the mother gives birth to a chimeric animal having the disrupted hnRNP A1 gene in its genome; (8) crossing the chimeric animal obtained in step (7) with a normal animal to obtain a heterozygous knockout animal; (9) repeating the crossing defined in step (8) at least 1 time to generate another heterozygous knockout animal; and (10) crossing the heterozygous knockout animals obtained in step (8) and (9) with each other to generate a homozygous or heterozygous hnRNP A1 knockout animal. Preferably, the crossing step defined in step (8) is repeated at least 2, 3, 4 or 5 times to generate the heterozygous knockout animals. More preferably, the crossing step defined in step (8) is repeated at least 5 times to generate the heterozygous knockout animals.
In a preferred embodiment, the non-human heterozygous knockout animal is a heterozygous hnRNP A1 knockout mouse.
5. Use of the Knockout Animals
The knockout animals of the present invention are useful for studying the function of hnRNP A1 gene and diseases wherein the hnRNP A1 gene is implicated, including neurodegenerative disease and cancer. Hence, the non-human hnRNP A1 knockout animals of the present disclosure are useful for identifying therapeutic compounds that may be useful in preventing and/or treating any of these diseases.
Accordingly, the present disclosure provides a method of screening a compound for potential use in prevention and/or treatment of neurodegenerative disease or cancer. The method includes steps of respectively administering a test compound to a non-human animal comprises a disruption in hnRNP A1 gene or primary cells or tissues derived therefrom and a wild-type non-human animal or primary cells or tissues derived therefrom; and assessing functions of exonic RNA splicing in each of the non-human animal, cell, or tissue defined above, prior to and after a given time period of the administration; and comparing the assessment results to determine effectiveness of the test compound.
In one embodiment, the non-human animal is a mouse, a hamster, a rat or a rabbit. In another embodiment, the non-human animal is a mouse.
In a further embodiment, the primary cells or tissues derived from the hnRNP A1 gene-disrupted mouse are prepared by a method well known in the art (Kazutoshi et al., Nature Protocols (2007), 2: 3081-3089; and Yen et al., Environmental Health Perspectives (2010), 118: 949-956). The primary cells can be fibroblasts from the non-human animal embryos or myoblasts from the neonatal non-human animal. The the non-human animal may be, but not limited to, mouse. Briefly, the process for preparing mouse embryonic fibroblasts (MEF) includes the following steps: (1) isolating mouse embryos at day 13.5 and removing the head, visceral tissues and gonads from the isolated embryos; (2) hashing out the remaining embryonic body and incubating in a solution containing trypsin and EDTA under 37° C.; (3) dissociating the embryonic body in appropriate medium to form a cell suspension; (4) centrifuging the cell suspension to enrich the MEFs; and (5) culturing the MEFs in appropriate medium with suitable cellular concentration. The primary myoblasts of can be prepared from the forelimb and hind limb of neonatal mouse through the following steps: (1) removing surrounding connective tissue and mincing the muscles into small pieces; (2) digesting the minced muscles with collagenase; (3) incubating the digested muscles with trypsin to dissociate cells; and (4) collecting the dissociated cells by centrifugation and incubating the cells in appropriate medium.
The following examples are provided to illustrate the present invention without, however, limiting the same thereto.
EXAMPLESThe process for generating the hnRNP A1 knockout mice and uses thereof of the present disclosure will be illustrated in further detail with reference to several examples below, which are not intended to limit the scope of the present disclosure.
Example 1 The Generation of hnRNP A1 Knockout Mice1.1 Constructing the Target Vector
The hnRNP A1 targeting vector was generated by deleting exons 2 to 8 of the hnRNP A1 gene. This targeting construct was created using recombineering techniques in a 129S7/AB2.2 bacterial artificial chromosome containing the hnRNP A1 gene (clone bMQ-281N24, Geneservice, Cambridge, UK). A loxP site was inserted before the exon 2 of hnRNP A1. More particularly, the loxP site was inserted between exon 1 and exon 2 of hnRNP A1 gene. A neomycin resistance gene was inserted into the hnRNP A1 gene for the enhancement of selecting positively targeted embryonic stem cells (ES) clones in the presence of neomycin analog G-418. A frt sites flanking the neomycin resistance cassette followed by another loxP site was then inserted behind exon 8. Specifically, “behind exon 8” means between exon 8 and exon 9.
1.2 Selection of Targeted Embryonic Stem (ES) Cell Clones
In order to incorporated the mutated hnRNP A1 gene in the targeting vector into the ES cells for targeting homologous recombination to occur, the targeting construct of Example 1.1 was electroporated into 129 ES cells. The transfected ES cells were then selected by neomycin analog G418. In principle, those ES cells that were targeted and thus carried the mutated hnRNP A1 alleles could survive in the culture environment containing G148 because of the presence of a built-in neomycin resistant gene in the mutated vector. The non-targeted wild type ES cells would die because of the lack of the neomycin gene in the presence of G418.
The surviving targeted ES cells clones were microscopically picked and cultured separately. The individually grown ES cell clones were harvested and isolated for genomic DNAs. The extracted DNAs were analysed on their restriction fragment patterns using genomic Southern blot technology to select for the replacement targeting through homologous recombination and to differentiate it from the unwanted gene insertion events. The neomycin resistance cassette was deleted by introduced Flp recombinase; and the gene segment flanked by the two loxP sites, containing exons from 2 to 8 of hnRNP A1, of the targeted ES cells was deleted by introduced Cre recombinase. The clones showed the band pattern of having 2 site were hnRNP A1 targeted +/− heterozygous knockouts. They were selected for blastocyst injection after expansion.
1.3 Generation of Mouse hnRNP A1 Knockout Line
The targeted ES cell clones of example 1.2 were expanded according to standard procedures. The ES cells were then microinjected into blastocysts recovered from female C57BL/6 mice. The injected blastocysts were re-implanted to female BALB/C mice as foster mothers for the embryos. Approximately 30 to 40 blastocysts were implanted to each foster mother. The foster mothers were maintained in sterile conditions. Litters were born 18-20 days later. Among the newly born pups there were 3 male and 2 female chimeras with different degree of agouti color furs. To determine whether these chimeras had targeted hnRNP A1 ES cells developed into germ cells, the chimeras were mated with the wild-type C57BL/6 mice to generate the F1 mice. The F1's were screened and genotyped for germline transmission.
PCR methods were used for genotyping the tail DNAs of the mice. The primers, A1U (5′-tatagcgggatgtgacgtgttttg-3′, SEQ ID NO: 5) and WT-L (5′-aatgaatcaacaccccgcaacaac-3′, SEQ ID NO: 6), were used to show the presence of the wild type allele. The deleted allele was detected by the primers A1U and KO-L (5′-actgcacccacaatgctttaagag-3′, SEQ ID NO: 7). Result is depicted in
The F1 mice were also analyzed for their expression of hnRNP A1 protein using western blot analysis. Briefly, mouse tissues such as heart and brain, were collected and homogenized in RIPA buffer (50 mM Tris-HCl, pH8, 1 mM EDTA, 150 mM NaCl, 1% NP40, 0.5% sodium deoxycholate, 1% SDS, 1× protease inhibitor cocktails and 1 mM PMSF) at 4° C. for 20 min. The lysates were subjected to SDS-PAGE and immunoblotting. The blots were probed with anti-hnRNP A1 antibody (Sigma, Saint Louis, Mo., USA)) or anti-beta-actin antibody (Santa Cruz, Santa Cruz, Calif., USA) and detected by ECL chemiluminescence kit (GE Healthcare, Piscataway, N.J., USA). Result is depicted in
The mice were bred in a specific pathogen-free facility and treated according to the Guide for the Care and Use of Laboratory Animals issued by National Research Council (Taiwan, Republic of China). Embryos of the hnRNP A1 heterozygotes, which were formally named as B6. 129-Hnrnpa1tm1Cfy , had been deposited in Rodent Model Resource Center of National Laboratory Animal Center (RMRC-NLAC) in Taiwan with the deposit No. RMRC13102. The hnRNP A1 heterozygotes carrying one deleted allele were interbred to achieve the homozygous hnRNP A1 null mice.
Example 2 Characterization of the hnRNP A1 Knockout Mice2.1 hnRNP A1−/− Mice Are Embryonic Lethality Or Dead After Birth
After heterozygous intercross as described in Example 1.3, 18 hnRNP A1+/+, hnRNP A1+/− and 8 hnRNP A1−/− pups were born among 10 litters. The heterozygous mice appeared completely normal and fertile. However, the hnRNP A1−/− pups showed small body size and none of homozygous mutant mice was alive after birth. In addition, the number of the homozygous mutant mice was lower than the predicted number of Mendel's Law of Inheritance. These results suggest that a mouse lack of hnRNP A1 results in embryonic lethality or immediately dead after birth.
In order to determine the embryonic lethality, we examined the genotype of embryos at E18.5 from heterozygous intercross. There were 20 hnRNP A1+/+, 36 hnRNP A1+/− and 16 hnRNP A1−/− embryos at E18.5 among 10 litters. The p value from chi-square analysis is 0.8007. The p value, greater than 0.05, means the genotype of the embryos following Mendel's Law of Inheritance of the ratio 1:2:1. In addition, the body length of hnRNP A1−/− embryos range from 1.0 to 2.1 cm, lower than the average body length of E18.5 (2.2-2.5 cm). This data indicates that the development of hnRNP A1−/− embryos ceased at different developmental ages. Overall, the results support the hypothesis that a mouse lack of hnRNP A1 results in embryonic lethality or immediately dead after birth.
2.2 hnRNP A1−/− Mice Display Embryonic Growth Retardation
In this example, morphological and histological properties of the hnRNP A1−/− mice at E18.5 were examined. The hnRNP A1−/− embryo displayed growth retardation (
2.3 Heterozygous hnRNP A1+/− Adult Mice Express Low hnRNP A1 Protein in Organs
Since the gene number of hnRNP A1 in heterozygous hnRNP A1+/− adult mice are lower than homozygous hnRNP A1+/+ mice. The protein levels of hnRNP A1 in the organs of these mice were determined. The organs, such lung, testis and brain, from these mice were collected and using Western blot to detect the amount of hnRNP A1 protein. The results showed that heterozygous hnRNP A1+/− adult mice expressed lower hnRNP A1 protein than hnRNP A1+/+ mice in these organs (
It will be understood that the above description of embodiments is given by way of example only and that various modifications may be made by those with ordinary skill in the art. The above specification, examples and data provide a complete description of the structure and use of exemplary embodiments of the invention. Although various embodiments of the invention have been described above with a certain degree of particularity, or with reference to one or more individual embodiments, those with ordinary skill in the art could make numerous alterations to the disclosed embodiments without departing from the spirit or scope of this invention.
All publication, patents and patent application are herein incorporated by reference in their entirety to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety.
Claims
1. A nucleic acid construct comprising a genetic engineered heterogeneous nuclear ribonucleoprotein (hnRNP) A1 gene, wherein a first locus of recombination sequence 1 is inserted before exon 2 of the hnRNP A1 gene, and recombination sequences 2 flanking a marker gene followed by a second locus of recombination sequence 1 are inserted behind exon 8 of the hnRNP A1 gene;
- wherein the recombination sequence 1 and recombination sequence 2 undergo recombination with the same recombination sequence at the other locus in the presence of their corresponding recombinase.
2. The nucleic acid construct of claim 1, wherein the marker gene detects the presence of the nucleic acid construct in a cell.
3. The nucleic acid construct of claim 1, wherein the marker gene is an antibiotic resistance gene, a reporter lacZ gene, or a herpes simplex virus thymidine kinase gene (HSV-tk).
4. The nucleic acid construct of claim 3, wherein the antibiotic resistance gene is neomycin-resistant gene.
5. The nucleic acid construct of claim 1, wherein the recombination sequence 1 is a crossover (x) in P1 (loxP) site and the recombination sequences 2 is a FLP recombinase target (frt) site.
6. The nucleic acid construct of claim 5, wherein the hnRNP A1 gene is disrupted by introduction of Cre recombinase and FLP recombinase.
7. A transgenic mouse whose genome comprising a homozygous disruption in hnRNP A1 gene, wherein the disruption results in the transgenic mouse having a damaged function of exonic RNA splicing, a reduced weight relative to a wild-type control mouse at embryonic stage, and perinatal mortality.
8. The transgenic mouse of claim 7, wherein the disruption affects at least two exons within the hnRNP A1 gene.
9. The transgenic mouse of claim 8, wherein the exons are exons 2 to 8.
10. A transgenic mouse whose genome comprising a heterozygous disruption in hnRNP A1 gene.
11. The transgenic mouse of claim 10, wherein the disruption affects at least two exons within the hnRNP A1 gene.
12. The transgenic mouse of claim 11, wherein the exons are exons 2 to 8.
13. The transgenic mouse of claim 10, wherein the transgenic mouse is predisposed to premature aging diseases and/or virus infective diseases.
14. A method of screening a compound for potential use in prevention and/or treatment of neurodegenerative disease or cancer, which comprises,
- (a) administering a test compound to the transgenic mouse of claim 7 or primary cells or tissues derived therefrom;
- (b) administering a test compound to a wild-type mouse or primary cells or tissues derived therefrom;
- (c) assessing functions of exonic RNA splicing in each of the mice, cell, or tissues from step (a) and (b), prior to and after a given time period of the administration; and
- (d) comparing the assessment results of step (c) to determine effectiveness of the test compound.
Type: Application
Filed: Aug 31, 2012
Publication Date: Mar 14, 2013
Applicant: KAOHSIUNG MEDICAL UNIVERSITY (Kaohsiung City)
Inventors: Yung-Fu Chang (Kaohsiung City), Ting-Yuan Liu (Kaohsiung City), Yuh-Jyh Jong (Kaohsiung City), Jan-Gowth Chang (Kaohsiung City)
Application Number: 13/600,635
International Classification: A01K 67/027 (20060101); A61K 49/00 (20060101); C12Q 1/02 (20060101); C12N 15/63 (20060101);
